+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Osteosarcoma (Oncology) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 1205 Pages
  • July 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5402616
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Drugs In Development, 2021, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 37, 24, 1, 37 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 7 and 3 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Osteosarcoma - Overview
  • Osteosarcoma - Therapeutics Development
Osteosarcoma - Therapeutics AssessmentOsteosarcoma - Companies Involved in Therapeutics DevelopmentOsteosarcoma - Drug ProfilesOsteosarcoma - Dormant ProjectsOsteosarcoma - Discontinued ProductsOsteosarcoma - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development for Osteosarcoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Osteosarcoma - Pipeline by Aadi Bioscience Inc, 2021
  • Osteosarcoma - Pipeline by Actuate Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by ADCendo ApS, 2021
  • Osteosarcoma - Pipeline by Advanced BioDesign, 2021
  • Osteosarcoma - Pipeline by Advaxis Inc, 2021
  • Osteosarcoma - Pipeline by Advenchen Laboratories LLC, 2021
  • Osteosarcoma - Pipeline by Allarity Therapeutics A/S, 2021
  • Osteosarcoma - Pipeline by AntiCancer Inc, 2021
  • Osteosarcoma - Pipeline by APEIRON Biologics AG, 2021
  • Osteosarcoma - Pipeline by API Co Ltd, 2021
  • Osteosarcoma - Pipeline by Arrowhead Pharmaceuticals Inc, 2021
  • Osteosarcoma - Pipeline by Astex Therapeutics Ltd, 2021
  • Osteosarcoma - Pipeline by AstraZeneca Plc, 2021
  • Osteosarcoma - Pipeline by Atlanthera, 2021
  • Osteosarcoma - Pipeline by Aurora BioPharma Inc, 2021
  • Osteosarcoma - Pipeline by Autolus Therapeutics Plc, 2021
  • Osteosarcoma - Pipeline by Bayer AG, 2021
  • Osteosarcoma - Pipeline by Bicycle Therapeutics Plc, 2021
  • Osteosarcoma - Pipeline by BioAtla Inc, 2021
  • Osteosarcoma - Pipeline by BioEclipse Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by BioMarck Pharmaceuticals Ltd, 2021
  • Osteosarcoma - Pipeline by Epeius Biotechnologies Corp, 2021
  • Osteosarcoma - Pipeline by Exelixis Inc, 2021
  • Osteosarcoma - Pipeline by GlaxoSmithKline Plc, 2021
  • Osteosarcoma - Pipeline by GlycoMimetics Inc, 2021
  • Osteosarcoma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2021
  • Osteosarcoma - Pipeline by HengRui YuanZheng Bio-Technology Co Ltd, 2021
  • Osteosarcoma - Pipeline by Hillstream BioPharma Inc, 2021
  • Osteosarcoma - Pipeline by Idera Pharmaceuticals Inc, 2021
  • Osteosarcoma - Pipeline by ImmunityBio Inc, 2021
  • Osteosarcoma - Pipeline by Incuron LLC, 2021
  • Osteosarcoma - Pipeline by Innova Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by Intezyne Inc, 2021
  • Osteosarcoma - Pipeline by Iovance Biotherapeutics Inc, 2021
  • Osteosarcoma - Pipeline by Ipsen SA, 2021
  • Osteosarcoma - Pipeline by Isofol Medical AB, 2021
  • Osteosarcoma - Pipeline by Iterion Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by ITM Isotopen Technologien Munchen AG, 2021
  • Osteosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Osteosarcoma - Pipeline by Joint Biosciences Ltd, 2021
  • Osteosarcoma - Pipeline by K-Group Beta Inc, 2021
  • Osteosarcoma - Pipeline by Komipharm International Co Ltd, 2021
  • Osteosarcoma - Pipeline by Kyowa Kirin Co Ltd, 2021
  • Osteosarcoma - Pipeline by MacroGenics Inc, 2021
  • Osteosarcoma - Pipeline by Mana Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by Mateon Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by MD Biosciences GmbH, 2021
  • Osteosarcoma - Pipeline by MediaPharma SRL, 2021
  • Osteosarcoma - Pipeline by Merck & Co Inc, 2021
  • Osteosarcoma - Pipeline by Merck KGaA, 2021
  • Osteosarcoma - Pipeline by MetCure Therapeutics LLC, 2021
  • Osteosarcoma - Pipeline by Moleculin Biotech Inc, 2021
  • Osteosarcoma - Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2021
  • Osteosarcoma - Pipeline by Nektar Therapeutics, 2021
  • Osteosarcoma - Pipeline by Nkarta Inc, 2021
  • Osteosarcoma - Pipeline by Novartis AG, 2021
  • Osteosarcoma - Pipeline by Oncolys BioPharma Inc, 2021
  • Osteosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, 2021
  • Osteosarcoma - Pipeline by OS Therapies LLC, 2021
  • Osteosarcoma - Pipeline by PEEL Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by Pfizer Inc, 2021
  • Osteosarcoma - Pipeline by Pimera Inc, 2021
  • Osteosarcoma - Pipeline by QSAM Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by Reven Pharmaceuticals Inc, 2021
  • Osteosarcoma - Pipeline by Scancell Holdings Plc, 2021
  • Osteosarcoma - Pipeline by Secura Bio Inc, 2021
  • Osteosarcoma - Pipeline by Shionogi & Co Ltd, 2021
  • Osteosarcoma - Pipeline by Singh Biotechnology LLC, 2021
  • Osteosarcoma - Pipeline by Sorrento Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, 2021
  • Osteosarcoma - Pipeline by Taithera Inc, 2021
  • Osteosarcoma - Pipeline by Transtarget Inc, 2021
  • Osteosarcoma - Pipeline by Umoja BioPharma Inc, 2021
  • Osteosarcoma - Pipeline by United Therapeutics Corp, 2021
  • Osteosarcoma - Pipeline by Vaccinex Inc, 2021
  • Osteosarcoma - Pipeline by Veana Therapeutics LLC, 2021
  • Osteosarcoma - Pipeline by Y-mAbs Therapeutics Inc, 2021
  • Osteosarcoma - Pipeline by Zentalis Pharmaceuticals Inc, 2021
  • Osteosarcoma - Dormant Projects, 2021
  • Osteosarcoma - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Osteosarcoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aadi Bioscience Inc
  • Actuate Therapeutics Inc
  • ADCendo ApS
  • Advanced BioDesign
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Allarity Therapeutics A/S
  • AntiCancer Inc
  • APEIRON Biologics AG
  • API Co Ltd
  • Arrowhead Pharmaceuticals Inc
  • Astex Therapeutics Ltd
  • AstraZeneca Plc
  • Atlanthera
  • Aurora BioPharma Inc
  • Autolus Therapeutics Plc
  • Bayer AG